{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:31:45Z","timestamp":1777613505887,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40290-020-00340-1","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T09:05:56Z","timestamp":1591607156000},"page":"257-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease?"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-7843","authenticated-orcid":false,"given":"Piotr","family":"Nehring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5851-2856","authenticated-orcid":false,"given":"Adam","family":"Przyby\u0142kowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"issue":"8","key":"340_CR1","first-page":"905","volume":"11","author":"C Maaser","year":"2017","unstructured":"Maaser C, Langholz E, Gordon H, Burisch J, Ellul P, Ramirez VH, et al. European Crohn's and colitis organisation topical review on environmental factors in IBD. J Crohns Colitis. 2017;11(8):905\u201320.","journal-title":"J Crohns Colitis"},{"issue":"11","key":"340_CR2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1038\/ajg.2014.246","volume":"109","author":"R Ungaro","year":"2014","unstructured":"Ungaro R, Bernstein CN, Gearry R, Hviid A, Kolho KL, Kronman MP, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol. 2014;109(11):1728\u201338.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"340_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, et al. The First European Evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239\u201354.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"340_CR4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","volume":"106","author":"SR Vavricka","year":"2011","unstructured":"Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"340_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","volume":"61","author":"M Makredes","year":"2009","unstructured":"Makredes M, Robinson D Jr, Bala M, Kimball AB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61(3):405\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"340_CR6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74(7):1373\u20138.","journal-title":"Ann Rheum Dis"},{"key":"340_CR7","doi-asserted-by":"crossref","first-page":"983902","DOI":"10.1155\/2013\/983902","volume":"2013","author":"N Skroza","year":"2013","unstructured":"Skroza N, Proietti I, Pampena R, La Viola G, Bernardini N, Nicolucci F, et al. Correlations between psoriasis and inflammatory bowel diseases. Biomed Res Int. 2013;2013:983902.","journal-title":"Biomed Res Int"},{"issue":"6","key":"340_CR8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clindermatol.2007.08.006","volume":"25","author":"E Christophers","year":"2007","unstructured":"Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529\u201334.","journal-title":"Clin Dermatol"},{"issue":"4","key":"340_CR9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2008.03.004","volume":"28","author":"W Ouyang","year":"2008","unstructured":"Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454\u201367.","journal-title":"Immunity"},{"issue":"8","key":"340_CR10","first-page":"962","volume":"85","author":"FI Lee","year":"1990","unstructured":"Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol. 1990;85(8):962\u20133.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"340_CR11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.2008.08779.x","volume":"159","author":"W Gulliver","year":"2008","unstructured":"Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008;159(Suppl 2):2\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"340_CR12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E. Psoriasis\u2013epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314\u201320.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"340_CR13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clindermatol.2013.11.001","volume":"32","author":"I Grozdev","year":"2014","unstructured":"Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014;32(3):343\u201350.","journal-title":"Clin Dermatol"},{"issue":"4","key":"340_CR14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","volume":"167","author":"G Girolomoni","year":"2012","unstructured":"Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717\u201324.","journal-title":"Br J Dermatol"},{"issue":"4","key":"340_CR15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5114\/pdia.2014.40954","volume":"31","author":"AG Shabgah","year":"2014","unstructured":"Shabgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol. 2014;31(4):256\u201361.","journal-title":"Postepy Dermatol Alergol"},{"issue":"12","key":"340_CR16","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"key":"340_CR17","doi-asserted-by":"crossref","unstructured":"Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441\u20138 e2.","DOI":"10.1016\/j.jaad.2016.10.027"},{"issue":"2","key":"340_CR18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2017.06.043","volume":"78","author":"SM Whitlock","year":"2018","unstructured":"Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2018;78(2):383\u201394.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"340_CR19","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","volume":"140","author":"W Strober","year":"2011","unstructured":"Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756\u201367.","journal-title":"Gastroenterology"},{"issue":"6","key":"340_CR20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","volume":"10","author":"W O'Connor Jr","year":"2009","unstructured":"O'Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol. 2009;10(6):603\u20139.","journal-title":"Nat Immunol"},{"issue":"11","key":"340_CR21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. Am J Gastroenterol. 2016;111(11):1599\u2013607.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"340_CR22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"1","key":"340_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clim.2003.09.013","volume":"110","author":"A Ogawa","year":"2004","unstructured":"Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110(1):55\u201362.","journal-title":"Clin Immunol"},{"issue":"1","key":"340_CR24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2008.09.019","volume":"377","author":"R Ito","year":"2008","unstructured":"Ito R, Kita M, Shin-Ya M, Kishida T, Urano A, Takada R, et al. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Bioph Res Co. 2008;377(1):12\u20136.","journal-title":"Biochem Bioph Res Co"},{"issue":"5","key":"340_CR25","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.20071978","volume":"205","author":"XXO Yang","year":"2008","unstructured":"Yang XXO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063\u201375.","journal-title":"J Exp Med"},{"issue":"5","key":"340_CR26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1468-3083.2008.03031.x","volume":"23","author":"AD Cohen","year":"2009","unstructured":"Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23(5):561\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"340_CR27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","volume":"43","author":"JR Maxwell","year":"2015","unstructured":"Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, et al. Differential Roles for Interleukin-23 and Interleukin-17 in intestinal immunoregulation. Immunity. 2015;43(4):739\u201350.","journal-title":"Immunity"},{"key":"340_CR28","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.14309\/crj.2018.56","volume":"5","author":"J Wang","year":"2018","unstructured":"Wang J, Bhatia A, Krugliak Cleveland N, Gupta N, Dalal S, Rubin DT, et al. Rapid onset of inflammatory bowel disease after receiving secukinumab infusion. ACG Case Rep J. 2018;5:e56.","journal-title":"ACG Case Rep J"},{"issue":"4","key":"340_CR29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"340_CR30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","volume":"50","author":"A Yamada","year":"2019","unstructured":"Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019;50(4):373\u201385.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"340_CR31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","volume":"77","author":"J Bagel","year":"2017","unstructured":"Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"340_CR32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaad.2016.07.058","volume":"76","author":"A Gottlieb","year":"2017","unstructured":"Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You RQ, Parneix A, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"340_CR33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","volume":"17","author":"TN Canavan","year":"2016","unstructured":"Canavan TN, Elmets CA, Cantrell WL, Evans JM, Elewski BE. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2016;17(1):33\u201347.","journal-title":"Am J Clin Dermatol"},{"key":"340_CR34","doi-asserted-by":"crossref","unstructured":"van de Kerkhof PCM, Griffiths CEM, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83.","DOI":"10.1016\/j.jaad.2016.03.024"},{"issue":"8","key":"340_CR35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s40261-019-00803-7","volume":"39","author":"W Fries","year":"2019","unstructured":"Fries W, Belvedere A, Cappello M, Orlando A, Trifiro G. inflammatory bowel disease onset during secukinumab treatment: real concern or just an expression of dysregulated immune response? Clin Drug Investig. 2019;39(8):799\u2013803.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"340_CR36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ced.14149","volume":"45","author":"ASW Lee","year":"2020","unstructured":"Lee ASW, Levell NJ, Shah SN, Gaffney K, Tremelling MAW. Severe colitis complicating secukinumab (Cosentyx((R)) ) therapy. Clin Exp Dermatol. 2020;45(3):344\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"340_CR37","doi-asserted-by":"crossref","unstructured":"Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2019.","DOI":"10.1016\/j.jaad.2019.05.095"},{"key":"340_CR38","doi-asserted-by":"crossref","unstructured":"Umezawa Y, Nakagawa H, Niiro H, Ootaki K, Japanese Brodalumab Study G. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016;30(11):1957\u201360.","DOI":"10.1111\/jdv.13785"},{"issue":"2","key":"340_CR39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"14","key":"340_CR40","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. New Engl J Med. 2015;373(14):1318\u201328.","journal-title":"New Engl J Med"},{"key":"340_CR41","doi-asserted-by":"crossref","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study G. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351.","DOI":"10.1111\/bjd.14702"},{"issue":"3","key":"340_CR42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1159\/000493922","volume":"12","author":"J Philipose","year":"2018","unstructured":"Philipose J, Ahmed M, Idiculla PS, Mulrooney SM, Gumaste VV. Severe de novo ulcerative colitis following ixekizumab therapy. Case Rep Gastroenterol. 2018;12(3):617\u201321.","journal-title":"Case Rep Gastroenterol"},{"issue":"4","key":"340_CR43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/1346-8138.13622","volume":"44","author":"H Saeki","year":"2017","unstructured":"Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355\u201362.","journal-title":"J Dermatol"},{"issue":"10086","key":"340_CR44","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327.","journal-title":"Lancet"},{"issue":"9993","key":"340_CR45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, Van De Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"1","key":"340_CR46","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12876-019-1067-0","volume":"19","author":"MK Smith","year":"2019","unstructured":"Smith MK, Pai J, Panaccione R, Beck P, Ferraz JG, Jijon H. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. BMC Gastroenterol. 2019;19(1):162.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"340_CR47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/pde.13081","volume":"34","author":"JB Eickstaedt","year":"2017","unstructured":"Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253\u201360.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"340_CR48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/apt.14822","volume":"48","author":"JM Bae","year":"2018","unstructured":"Bae JM, Lee HH, Lee BI, Lee KM, Eun SH, Cho ML, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196\u2013205.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"340_CR49","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","volume":"30","author":"D Wendling","year":"2014","unstructured":"Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin. 2014;30(12):2515\u201321.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"340_CR50","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00296-018-4165-3","volume":"38","author":"S Tolu","year":"2018","unstructured":"Tolu S, Rezvani A, Hindioglu N, Calkin KM. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature. Rheumatol Int. 2018;38(11):2157\u201362.","journal-title":"Rheumatol Int"},{"issue":"6","key":"340_CR51","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","volume":"61","author":"A O'Toole","year":"2016","unstructured":"O'Toole A, Lucci M, Korzenik J. Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD Referral Center and the FDA. Dig Dis Sci. 2016;61(6):1772\u20134.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"340_CR52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","volume":"79","author":"E Toussirot","year":"2012","unstructured":"Toussirot E, Houvenagel E, Goeb V, Fouache D, Martin A, Le Dantec P, et al. Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: a nationwide series. Jt Bone Spine. 2012;79(5):457\u201363.","journal-title":"Jt Bone Spine"},{"issue":"3","key":"340_CR53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/apt.15370","volume":"50","author":"J Korzenik","year":"2019","unstructured":"Korzenik J, Larsen MD, Nielsen J, Kjeldsen J, Norgard BM. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFalpha agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(3):289\u201394.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-020-00340-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-020-00340-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-020-00340-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T23:49:00Z","timestamp":1623109740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-020-00340-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["340"],"URL":"https:\/\/doi.org\/10.1007\/s40290-020-00340-1","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"8 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for publication of the review. Open Access has been covered by The Medical University of Warsaw.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors declare no conflicts of interest related to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}